A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors

Montero Alberto J.; Kwon Deukwoo; Flores Aurea; Kovacs Krisztina; Trent Jonathan C.; Benedetto Pasquale; Rocha-Lima Caio; Merchan Jaime R.

首页> 外文期刊>Clinical cancer research: an official journal of the American Association for Cancer Research >A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors

【24h】

A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors

机译：晚期实体瘤患者每周或每三周伊沙贝比隆和每日舒尼替尼的I期临床，药代动力学和药效学研究

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Purpose: To evaluate the safety, MTD, pharmacokinetics/pharmacodynamics, and early clinical activity of ixabepilone given either weekly or every 3 weeks in combination with daily sunitinib in patients with advanced solid tumors.

机译：目的：为了评估晚期实体瘤患者每周或每3周给予ixabepilone与每日舒尼替尼联合使用的安全性，MTD，药代动力学/药效学和早期临床活性。

著录项

来源
《Clinical cancer research: an official journal of the American Association for Cancer Research》 |2016年第13期|共9页
作者
Montero Alberto J.; Kwon Deukwoo; Flores Aurea; Kovacs Krisztina; Trent Jonathan C.; Benedetto Pasquale; Rocha-Lima Caio; Merchan Jaime R.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors [J] . Montero Alberto J., Kwon Deukwoo, Flores Aurea, Clinical cancer research: an official journal of the American Association for Cancer Research . 2016,第13期

机译：晚期实体瘤患者每周或每三周伊沙贝比隆和每日舒尼替尼的I期临床，药代动力学和药效学研究
2. Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumors [J] . Toshio Shimizu, Noboru Yamamoto, Yasuhide Yamada, Cancer Chemotherapy and Pharmacology . 2008,第5期

机译：在日本难治性实体瘤患者中，每三周输注一次埃博霉素B类似物伊沙贝比隆（BMS-247550）的I期临床和药代动力学研究
3. Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors. [J] . Tabernero J, Rojo F, Marimon I, Journal of Clinical Oncology . 2005,第11期

机译：晚期实体瘤患者每周一次1小时和24小时输注BMS-214662（一种法尼基转移酶抑制剂）的I期药代动力学和药效学研究。
4. Phase I Clinical Trial with Her-2 B-Cell Chimeric and MultiEpitope Based Peptide Vaccines in Patients with Metastatic and/or Recurrent Solid Tumors [C] . Pravin T.P. Kaumaya, Kevin Chu Foy, Joan Garrett American Peptide Symposium . 2009

机译：患者临床试验与患有转移和/或复发性固体瘤的患者的HER-2 B细胞嵌合和多型肽疫苗
5. Evaluation of the pharmacokinetic-pharmacodynamic relationship, metabolism and plasma protein binding of the novel antitumor agent, 2-methoxyestradiol (2ME2), following oral administration in patients with solid tumors. [D] . Lakhani, Nehal Jagdish. 2005

机译：实体瘤患者口服后评估新型抗肿瘤药2-甲氧基雌二醇（2ME2）的药代动力学与药效关系，代谢和血浆蛋白结合。
6. A Phase I Clinical Pharmacokinetic and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors [O] . Alberto J. Montero, Deukwoo Kwon, Aurea Flores, -1

机译：晚期实体瘤患者每周或每三周伊沙贝比隆和每日舒尼替尼的I期临床药代动力学和药效学研究
7. A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors [O] . Alberto J. Montero, Deukwoo Kwon, Aurea Flores, 2016

机译：一期临床，药代动力学和药效学研究每周或每三周Ixabepilone和晚期阳光患者的晚期实体瘤患者

A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅